LRRC8D

Across TCGA pan-cancer cohorts, LRRC8D mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of LRRC8D’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where LRRC8D mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LRRC8D is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where LRRC8D tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRC8D mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.372	<.001	9	view →
LSCC	Female	All	+0.427	<.001	8	view →
HNSC	Male	All	+0.411	<.001	8	view →
PDAC	All	All	−0.371	.007	4	view →
LUAD	Male	All	−0.223	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

LRRC8D–CCRCC

Open the CCRCC breakdown →